Ane Abad-Motos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ane Abad-Motos has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Javier Ripollés-Melchor
Department of Anaesthesiology, Hospital Universitario Infanta Leonor, Madrid, Spain
18 shared publications - Alfredo Abad-Gurumeta
Department of Anesthesiology, Infanta Leonor Hospital, 28031 Madrid, Spain
7 shared publications - José Antonio García-Erce
Banco de Sangre y Tejidos de Navarra, Pamplona, Navarra, España; Aragón Health Research Institute (IACS), Aragon Institute for Health Research (IIS Aragon), Zaragoza; Grupo Español de Rehabilitación Multimodal (GERM), Zaragoza, España; Grupo de Investigación Gestión en el Paciente Sangrante-PBM, Instituto de Investigación Sanitaria, Hospital Universitaria La Paz (IdiPAZ), Madrid, España
7 shared publications - César Aldecoa
Hospital Universitario Rio Hortega
6 shared publications Alfredo Abad-Gurumeta
Department of Anesthesia and Perioperative Medicine, Infanta Leonor University Hospital, Madrid, Spain
5 shared publications- Carlos Jericó
Service of Internal Medicine, Hospital de Sant Joan Despí Moisès Broggi, Sant Joan Despí, Barcelona, Spain
4 shared publications
Latest Publications
- 11 October 2026
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 70 (10) , e70355
Postoperative Vasoactive Exposure Patterns and Outcomes After Non‐Cardiac Surgery: A Prespecified Analysis of the SQUEEZE Cohort
Background: Postoperative vasoactive therapy is usually summarised by its presence or duration, although haemodynamic support evolves over time. We investigated whether reproducible postoperative vasoactive exposure patterns provide prognostic information beyond the duration of postoperative vasoactive therapy. Methods: We performed a prespecified substudy of the international SQUEEZE cohort. Adults receiving postoperative vasoactive infusion within seven postoperative days after non‐cardiac surgery were included. Unsupervised k‐means clustering identified exposure patterns using duration of postoperative vasoactive infusion, cumulative vasoactive agent‐days, and peak number of concurrent agents. Associations with 30‐day mortality, acute kidney injury (AKI), and hospital length of stay were assessed using multivariable regression. A prespecified landmark analysis evaluated early postoperative vasoactive exposure burden during postoperative days 0–1. Results: Among 25,672 patients, 6676 (26.0%) received postoperative vasoactive infusion. Four reproducible exposure patterns were identified. Adjusted 30‐day mortality ranged from 9.7% in the low‐burden pattern to 35.3% in the high‐burden pattern but was not strictly monotonic, whereas adjusted AKI risk increased from 28.0% to 56.0% across patterns. In covariate‐adjusted models fitted to the same complete‐case cohort, discrimination was higher when exposure pattern rather than duration was included (AUC 0.818 vs. 0.795), while adding duration to pattern classification resulted in little additional discrimination (AUC 0.819). Findings were consistent in the early postoperative landmark analysis. Conclusions: Postoperative vasoactive exposure follows reproducible patterns characterised by persistence and overall treatment burden rather than binary classification alone. These patterns were associated with mortality, AKI, and hospital length of stay, and provided prognostic information beyond duration alone. Editorial Comment: This substudy and analysis of the SQUEEZE cohort, which represents a large sample of cases with focus on post‐operative vasopressor treatments, shows that more intensive vasopressor therapy was associated with worse postoperative outcomes, including for mortality and 30 days and postoperative acute kidney injury occurrence. Trial Registration: ClinicalTrials.gov identifier: NCT03805230
- 11 October 2026
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 70 (10) , e70355
Postoperative Vasoactive Exposure Patterns and Outcomes After Non‐Cardiac Surgery: A Prespecified Analysis of the SQUEEZE Cohort
Background: Postoperative vasoactive therapy is usually summarised by its presence or duration, although haemodynamic support evolves over time. We investigated whether reproducible postoperative vasoactive exposure patterns provide prognostic information beyond the duration of postoperative vasoactive therapy. Methods: We performed a prespecified substudy of the international SQUEEZE cohort. Adults receiving postoperative vasoactive infusion within seven postoperative days after non‐cardiac surgery were included. Unsupervised k‐means clustering identified exposure patterns using duration of postoperative vasoactive infusion, cumulative vasoactive agent‐days, and peak number of concurrent agents. Associations with 30‐day mortality, acute kidney injury (AKI), and hospital length of stay were assessed using multivariable regression. A prespecified landmark analysis evaluated early postoperative vasoactive exposure burden during postoperative days 0–1. Results: Among 25,672 patients, 6676 (26.0%) received postoperative vasoactive infusion. Four reproducible exposure patterns were identified. Adjusted 30‐day mortality ranged from 9.7% in the low‐burden pattern to 35.3% in the high‐burden pattern but was not strictly monotonic, whereas adjusted AKI risk increased from 28.0% to 56.0% across patterns. In covariate‐adjusted models fitted to the same complete‐case cohort, discrimination was higher when exposure pattern rather than duration was included (AUC 0.818 vs. 0.795), while adding duration to pattern classification resulted in little additional discrimination (AUC 0.819). Findings were consistent in the early postoperative landmark analysis. Conclusions: Postoperative vasoactive exposure follows reproducible patterns characterised by persistence and overall treatment burden rather than binary classification alone. These patterns were associated with mortality, AKI, and hospital length of stay, and provided prognostic information beyond duration alone. Editorial Comment: This substudy and analysis of the SQUEEZE cohort, which represents a large sample of cases with focus on post‐operative vasopressor treatments, shows that more intensive vasopressor therapy was associated with worse postoperative outcomes, including for mortality and 30 days and postoperative acute kidney injury occurrence. Trial Registration: ClinicalTrials.gov identifier: NCT03805230
- 28 September 2026
- Published by Wolters Kluwer Health in Anesthesiology
Intraoperative blood pressure targeting in noncardiac surgery: a Bayesian random-effects meta-analysis of randomized trials
Background: Whether protocolized intraoperative arterial pressure-targeting strategies provide incremental benefit beyond contemporary usual care remains uncertain. We performed a Bayesian meta-analysis of randomized trials in major noncardiac surgery. Methods: MEDLINE, Embase, and Cochrane CENTRAL were searched from inception to January 5, 2026, with additional literature surveillance through June 29, 2026. Randomized trials comparing protocolized intraoperative arterial pressure-targeting strategies with usual care or lower-pressure approaches were included. The primary outcome was all-cause mortality; secondary outcomes were acute kidney injury (AKI) and myocardial injury after noncardiac surgery (MINS). Bayesian random-effects meta-analysis was prespecified as the primary analytical framework, with confirmatory frequentist analyses. Results: Fifteen randomized trials met the inclusion criteria. Mortality (13 trials) remained centered around an OR of 1.00 (frequentist OR 1.00, 95% CI 0.83–1.21; Bayesian median OR 1.00, 95% CrI 0.73–1.38), with wide Bayesian prediction intervals (OR 0.56–1.78). AKI (14 trials) showed the most favorable estimates (frequentist OR 0.87, 95% CI 0.73–1.03; Bayesian median OR 0.88, 95% CrI 0.70–1.05), but estimates remained compatible with no clinically important benefit, heterogeneity was moderate, and leave-one-out analyses, excluding each trial in turn, showed sensitivity to individual-trial exclusion. MINS (8 trials) likewise remained compatible with no treatment effect (frequentist OR 1.04, 95% CI 0.93–1.15; Bayesian median OR 1.05, 95% CrI 0.90–1.26). Exploratory analyses suggested that any potential renal benefit may depend on the broader hemodynamic context in which arterial pressure targets are implemented. Conclusions: Protocolized intraoperative arterial pressure-targeting strategies did not demonstrate a consistent incremental benefit over contemporary usual care in major noncardiac surgery. Mortality and MINS remained compatible with no treatment effect. Although AKI showed the most favorable estimates, the evidence remained uncertain, was sensitive to individual-trial exclusion, and should be interpreted cautiously.
- 28 September 2026
- Published by Wolters Kluwer Health in Anesthesiology
Intraoperative blood pressure targeting in noncardiac surgery: a Bayesian random-effects meta-analysis of randomized trials
Background: Whether protocolized intraoperative arterial pressure-targeting strategies provide incremental benefit beyond contemporary usual care remains uncertain. We performed a Bayesian meta-analysis of randomized trials in major noncardiac surgery. Methods: MEDLINE, Embase, and Cochrane CENTRAL were searched from inception to January 5, 2026, with additional literature surveillance through June 29, 2026. Randomized trials comparing protocolized intraoperative arterial pressure-targeting strategies with usual care or lower-pressure approaches were included. The primary outcome was all-cause mortality; secondary outcomes were acute kidney injury (AKI) and myocardial injury after noncardiac surgery (MINS). Bayesian random-effects meta-analysis was prespecified as the primary analytical framework, with confirmatory frequentist analyses. Results: Fifteen randomized trials met the inclusion criteria. Mortality (13 trials) remained centered around an OR of 1.00 (frequentist OR 1.00, 95% CI 0.83–1.21; Bayesian median OR 1.00, 95% CrI 0.73–1.38), with wide Bayesian prediction intervals (OR 0.56–1.78). AKI (14 trials) showed the most favorable estimates (frequentist OR 0.87, 95% CI 0.73–1.03; Bayesian median OR 0.88, 95% CrI 0.70–1.05), but estimates remained compatible with no clinically important benefit, heterogeneity was moderate, and leave-one-out analyses, excluding each trial in turn, showed sensitivity to individual-trial exclusion. MINS (8 trials) likewise remained compatible with no treatment effect (frequentist OR 1.04, 95% CI 0.93–1.15; Bayesian median OR 1.05, 95% CrI 0.90–1.26). Exploratory analyses suggested that any potential renal benefit may depend on the broader hemodynamic context in which arterial pressure targets are implemented. Conclusions: Protocolized intraoperative arterial pressure-targeting strategies did not demonstrate a consistent incremental benefit over contemporary usual care in major noncardiac surgery. Mortality and MINS remained compatible with no treatment effect. Although AKI showed the most favorable estimates, the evidence remained uncertain, was sensitive to individual-trial exclusion, and should be interpreted cautiously.
- 2 September 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (10) , 2838-2847
Perioperative Hemoglobin Trajectory and Hemoglobin Decrease in Major Abdominal Surgery
Background: Most studies evaluate perioperative hemoglobin at a single time point despite substantial changes across the perioperative period. We examined whether perioperative hemoglobin trajectory and perioperative hemoglobin decrease were associated with postoperative outcomes after major abdominal surgery. Methods: We performed a secondary analysis of the international POSTVenTT cohort, a prospective multicentre observational study of adults undergoing major abdominal surgery. Hemoglobin trajectory was defined according to anemia status preoperatively and at hospital discharge. Perioperative hemoglobin decrease was defined as the difference between preoperative and discharge hemoglobin concentration. Mixed‐effects logistic regression models adjusted for predefined clinical covariates and center clustering were used to evaluate associations with postoperative complications, postoperative transfusion, and 30‐day readmission. Results: Among 5302 patients, 3735 had both preoperative and discharge hemoglobin measurements and were included in trajectory analyses. Compared with patients without perioperative anemia, persistent anemia was associated with the higher odds of postoperative complications, postoperative transfusion, and 30‐day readmission, whereas new postoperative anemia showed similar but smaller associations. Greater perioperative hemoglobin decrease was associated with higher odds of postoperative complications. For each 10 g/L decrease, the odds of any postoperative complication increased by 35% (OR 1.35, 95% CI 1.26–1.45) and major complication by 49% (OR 1.49, 1.35–1.64). Associations persisted after accounting for transfusion exposure and baseline hemoglobin. Conclusions: Perioperative hemoglobin trajectory and perioperative hemoglobin decrease were associated with postoperative complications and 30‐day readmission after major abdominal surgery. Greater hemoglobin decrease remained associated with adverse outcomes after accounting for transfusion exposure and baseline hemoglobin. Trial Registration: The POSTVenTT study was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12621001517864; 8 November 2021). The trial protocol was approved by the South Metropolitan Health Service (Western Australia) Health Research Ethics Committee (EC00265), the Western Australia Research Governance System (RCG 4477), with local ethics and governance confirmed at each site before patient recruitment
- 2 September 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (10) , 2838-2847
Perioperative Hemoglobin Trajectory and Hemoglobin Decrease in Major Abdominal Surgery
Background: Most studies evaluate perioperative hemoglobin at a single time point despite substantial changes across the perioperative period. We examined whether perioperative hemoglobin trajectory and perioperative hemoglobin decrease were associated with postoperative outcomes after major abdominal surgery. Methods: We performed a secondary analysis of the international POSTVenTT cohort, a prospective multicentre observational study of adults undergoing major abdominal surgery. Hemoglobin trajectory was defined according to anemia status preoperatively and at hospital discharge. Perioperative hemoglobin decrease was defined as the difference between preoperative and discharge hemoglobin concentration. Mixed‐effects logistic regression models adjusted for predefined clinical covariates and center clustering were used to evaluate associations with postoperative complications, postoperative transfusion, and 30‐day readmission. Results: Among 5302 patients, 3735 had both preoperative and discharge hemoglobin measurements and were included in trajectory analyses. Compared with patients without perioperative anemia, persistent anemia was associated with the higher odds of postoperative complications, postoperative transfusion, and 30‐day readmission, whereas new postoperative anemia showed similar but smaller associations. Greater perioperative hemoglobin decrease was associated with higher odds of postoperative complications. For each 10 g/L decrease, the odds of any postoperative complication increased by 35% (OR 1.35, 95% CI 1.26–1.45) and major complication by 49% (OR 1.49, 1.35–1.64). Associations persisted after accounting for transfusion exposure and baseline hemoglobin. Conclusions: Perioperative hemoglobin trajectory and perioperative hemoglobin decrease were associated with postoperative complications and 30‐day readmission after major abdominal surgery. Greater hemoglobin decrease remained associated with adverse outcomes after accounting for transfusion exposure and baseline hemoglobin. Trial Registration: The POSTVenTT study was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12621001517864; 8 November 2021). The trial protocol was approved by the South Metropolitan Health Service (Western Australia) Health Research Ethics Committee (EC00265), the Western Australia Research Governance System (RCG 4477), with local ethics and governance confirmed at each site before patient recruitment
- 14 March 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (4) , 783-784
Emergency Laparotomy, Team Performance, and the Architecture of Recovery
- 14 March 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (4) , 783-784
Emergency Laparotomy, Team Performance, and the Architecture of Recovery
- Open Access
- 28 March 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (7) , 761
Intrathecal Morphine in Major Abdominal and Thoracic Surgery: Observational Study
Introduction: Optimal control of acute postoperative pain after major surgery accelerates the recovery process, shortens hospital stays, and minimizes healthcare costs. Intrathecal morphine is a simple, safe, and reliable regional technique that provides prolonged analgesia, useful in a wide variety of procedures. Materials and Methods: A retrospective observational study was conducted on patients who underwent various major abdominal or thoracic surgical procedures and were administered intrathecal morphine between January 2018 and December 2021. The primary objective was to establish the safety of the technique in terms of the incidence of early and late respiratory depression, atelectasis, the need for respiratory support, and the possible association of these complications with the presence of respiratory pathologies such as chronic obstructive pulmonary disease (COPD) or sleep apnea–hypopnea syndrome (SAHS) and obesity or smoking habit. Secondary objectives included recording the consumption of rescue intravenous (IV) morphine in the first postoperative 24 h, the incidence of PONV, and the incidence of late postoperative complications (at 90 days) such as pneumonia, readmission rates, and reoperation rates. Hospital stay and mortality were also recorded. Results: A total of 484 patients were included in the study. No patient experienced respiratory depression. Atelectasis occurred in 2.07% of patients. Respiratory support with non-invasive mechanical ventilation (NIMV) or high-flow oxygen therapy (HFOT) was required by 1.86% of patients. In total, 51% of patients required rescue IV morphine (average 6.98 mg), with a rate significantly higher in the thoracic and general surgery groups compared to urological surgery. The incidence of postoperative nausea and vomiting (PONV) was 30.37%. Regarding other secondary objectives, readmissions, reoperations, and mortality rates were significantly higher in patients undergoing urological and thoracic surgery compared to those undergoing general surgery. Conclusions: The administration of intrathecal morphine for the control of acute postoperative pain after major surgery can be considered as a safe technique that fits perfectly within the set of measures for a multimodal approach to pain management in major abdominal and thoracic surgery.
- 28 March 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (7) , 761
Open AccessIntrathecal Morphine in Major Abdominal and Thoracic Surgery: Observational Study
Introduction: Optimal control of acute postoperative pain after major surgery accelerates the recovery process, shortens hospital stays, and minimizes healthcare costs. Intrathecal morphine is a simple, safe, and reliable regional technique that provides prolonged analgesia, useful in a wide variety of procedures. Materials and Methods: A retrospective observational study was conducted on patients who underwent various major abdominal or thoracic surgical procedures and were administered intrathecal morphine between January 2018 and December 2021. The primary objective was to establish the safety of the technique in terms of the incidence of early and late respiratory depression, atelectasis, the need for respiratory support, and the possible association of these complications with the presence of respiratory pathologies such as chronic obstructive pulmonary disease (COPD) or sleep apnea–hypopnea syndrome (SAHS) and obesity or smoking habit. Secondary objectives included recording the consumption of rescue intravenous (IV) morphine in the first postoperative 24 h, the incidence of PONV, and the incidence of late postoperative complications (at 90 days) such as pneumonia, readmission rates, and reoperation rates. Hospital stay and mortality were also recorded. Results: A total of 484 patients were included in the study. No patient experienced respiratory depression. Atelectasis occurred in 2.07% of patients. Respiratory support with non-invasive mechanical ventilation (NIMV) or high-flow oxygen therapy (HFOT) was required by 1.86% of patients. In total, 51% of patients required rescue IV morphine (average 6.98 mg), with a rate significantly higher in the thoracic and general surgery groups compared to urological surgery. The incidence of postoperative nausea and vomiting (PONV) was 30.37%. Regarding other secondary objectives, readmissions, reoperations, and mortality rates were significantly higher in patients undergoing urological and thoracic surgery compared to those undergoing general surgery. Conclusions: The administration of intrathecal morphine for the control of acute postoperative pain after major surgery can be considered as a safe technique that fits perfectly within the set of measures for a multimodal approach to pain management in major abdominal and thoracic surgery.
- Open Access
- 20 February 2023
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 67 (5) , 629-639
Identification of the haemoglobin level associated with a lower risk of complications after total hip and knee arthroplasty
Background: Preoperative anaemia is associated with poor outcomes in surgical patients, but the preoperative haemoglobin cut‐off that determines lower morbidity in total knee arthroplasty (TKA) and total hip arthroplasty (THA) is not well established.Methods: Planned secondary analysis of data collected during a multicentre cohort study of patients undergoing THA and TKA in 131 Spanish hospitals during a single 2‐month recruitment period. Anaemia was defined as haemoglobin −1 for females and < 13 g dl−1 for males. The primary outcome was the number of patients with 30‐day in‐hospital postoperative complications according to European Perioperative Clinical Outcome definitions and specific surgical TKA and THA complications. Secondary outcomes included the number of patients with 30‐day moderate‐to‐severe complications, red blood cell transfusion, mortality, and length of hospital stay. Binary logistic regression models were constructed to assess association between preoperative Hb concentrations and postoperative complications, and variables significantly associated with the outcome were included in the multivariate model. The study sample was divided into 11 groups based on preoperative Hb values in an effort to identify the threshold at which increased postoperative complications occurred.Results: A total of 6099 patients were included in the analysis (3818 THA and 2281 TKA), of whom 8.8% were anaemic. Patients with preoperative anaemia were more likely to suffer overall complications (111/539, 20.6% vs. 563/5560, 10.1%, p < .001) and moderate‐to‐severe complications (67/539, 12.4% vs. 284/5560, 5.1%, p < .001). Multivariable analysis showed preoperative haemoglobin ≥14 g dl−1 was associated with fewer postoperative complications.Conclusion: Preoperative haemoglobin ≥14 g dl−1 is associated with a lower risk of postoperative complications in patients undergoing primary TKA and THA.
- 20 February 2023
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 67 (5) , 629-639
Open AccessIdentification of the haemoglobin level associated with a lower risk of complications after total hip and knee arthroplasty
Background: Preoperative anaemia is associated with poor outcomes in surgical patients, but the preoperative haemoglobin cut‐off that determines lower morbidity in total knee arthroplasty (TKA) and total hip arthroplasty (THA) is not well established.Methods: Planned secondary analysis of data collected during a multicentre cohort study of patients undergoing THA and TKA in 131 Spanish hospitals during a single 2‐month recruitment period. Anaemia was defined as haemoglobin −1 for females and < 13 g dl−1 for males. The primary outcome was the number of patients with 30‐day in‐hospital postoperative complications according to European Perioperative Clinical Outcome definitions and specific surgical TKA and THA complications. Secondary outcomes included the number of patients with 30‐day moderate‐to‐severe complications, red blood cell transfusion, mortality, and length of hospital stay. Binary logistic regression models were constructed to assess association between preoperative Hb concentrations and postoperative complications, and variables significantly associated with the outcome were included in the multivariate model. The study sample was divided into 11 groups based on preoperative Hb values in an effort to identify the threshold at which increased postoperative complications occurred.Results: A total of 6099 patients were included in the analysis (3818 THA and 2281 TKA), of whom 8.8% were anaemic. Patients with preoperative anaemia were more likely to suffer overall complications (111/539, 20.6% vs. 563/5560, 10.1%, p < .001) and moderate‐to‐severe complications (67/539, 12.4% vs. 284/5560, 5.1%, p < .001). Multivariable analysis showed preoperative haemoglobin ≥14 g dl−1 was associated with fewer postoperative complications.Conclusion: Preoperative haemoglobin ≥14 g dl−1 is associated with a lower risk of postoperative complications in patients undergoing primary TKA and THA.
- Open Access
- 28 May 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (11) , 3042
Relationship between ABO Blood Group Distribution and COVID-19 Infection in Patients Admitted to the ICU: A Multicenter Observational Spanish Study
Since the beginning of the COVID-19 pandemic in December 2019, a relationship between the ABO blood group type and the novel coronavirus SARS-CoV-2, the etiological agent of COVID-19, has been reported, noting that individuals with the O blood group are the least likely to be infected. Spain is one of the most badly affected countries worldwide, with high rates of patients diagnosed, hospitalized, and deceased due to COVID-19 infection. The present study aimed to analyze the possible relationship of ABO in COVID-19 patients hospitalized in different Spanish centers during the first wave of the COVID-19 pandemic, for which the ABO group was available. Physicians from the transfusion services of different Spanish hospitals, who have developed a multicenter retrospective observational study, were invited to participate voluntarily in the research and 12,115 patients with COVID-19 infection were admitted to the nine participating hospitals. The blood group was known in 1399 cases (11.5%), of which 365 (26.1%) were admitted to the ICU. Regarding the distribution of ABO blood groups, a significant increase in the non-O blood groups and reduction for the O blood group was observed in patients hospitalized due to COVID-19, compared to the reference general population. Among the patients admitted to the ICU, after multivariate analysis, adjusted for the rest of the confounding variables, patients with the O blood group presented a significantly lower risk for admission to the ICU. We conclude that an association was observed between patients with the O blood group and their lower susceptibility to SARS-CoV-2 infection, both for those admitted to the hospitalization ward and for those who required admission to the ICU.
- 28 May 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (11) , 3042
Open AccessRelationship between ABO Blood Group Distribution and COVID-19 Infection in Patients Admitted to the ICU: A Multicenter Observational Spanish Study
Since the beginning of the COVID-19 pandemic in December 2019, a relationship between the ABO blood group type and the novel coronavirus SARS-CoV-2, the etiological agent of COVID-19, has been reported, noting that individuals with the O blood group are the least likely to be infected. Spain is one of the most badly affected countries worldwide, with high rates of patients diagnosed, hospitalized, and deceased due to COVID-19 infection. The present study aimed to analyze the possible relationship of ABO in COVID-19 patients hospitalized in different Spanish centers during the first wave of the COVID-19 pandemic, for which the ABO group was available. Physicians from the transfusion services of different Spanish hospitals, who have developed a multicenter retrospective observational study, were invited to participate voluntarily in the research and 12,115 patients with COVID-19 infection were admitted to the nine participating hospitals. The blood group was known in 1399 cases (11.5%), of which 365 (26.1%) were admitted to the ICU. Regarding the distribution of ABO blood groups, a significant increase in the non-O blood groups and reduction for the O blood group was observed in patients hospitalized due to COVID-19, compared to the reference general population. Among the patients admitted to the ICU, after multivariate analysis, adjusted for the rest of the confounding variables, patients with the O blood group presented a significantly lower risk for admission to the ICU. We conclude that an association was observed between patients with the O blood group and their lower susceptibility to SARS-CoV-2 infection, both for those admitted to the hospitalization ward and for those who required admission to the ICU.
- Open Access
- 24 May 2022
- Published by Elsevier in The Lancet Global Health
- Vol. 10 (7) , e1003-e1011
Effects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study
- 24 May 2022
- Published by Elsevier in The Lancet Global Health
- Vol. 10 (7) , e1003-e1011
Open AccessEffects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study
- 20 April 2022
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 407 (6) , 2293-2300
Early Return to Intended Oncologic Therapy after implementation of an Enhanced Recovery After Surgery pathway for gastric cancer surgery
Purpose Time to initiation and completion of adjuvant therapy are critical to improve postoperative oncologic outcomes. This study aims to determine whether an Enhanced Recovery After Surgery (ERAS) pathway for gastric cancer surgery promotes early Return to Intended Oncologic Therapy (RIOT). Methods This is a before-after intervention study including patients with gastric adenocarcinoma who underwent surgery from January 2016 to January 2021. Two periods were denoted based upon the implementation date of our institutional ERAS pathway (June 2018). Our primary outcome was time to RIOT after surgery. Hodges-Lehmann analysis was used to estimate median differences of non-parametric outcomes. Results Seventy patients with gastric adenocarcinoma were included (35 in pre-ERAS period and 35 in post-ERAS period). Fourteen of the pre-ERAS and twenty-two patients of the post-ERAS period received adjuvant therapy. Time to RIOT was reduced in the post-ERAS period (median 39 days, IQR 31–49) by 12 days (95% CI 3–14 days, p = 0.01) compared to the pre-ERAS period (median 51 days, IQR 42–62). Length of hospital stay (LOS) was lower in the ERAS group (6 days, IQR 5–11 vs 10 days, IQR 8–13, p < 0.01). Conclusion Our institutional ERAS pathway for gastric cancer surgery was associated with earlier RIOT and shorter LOS.
- 20 April 2022
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 407 (6) , 2293-2300
Early Return to Intended Oncologic Therapy after implementation of an Enhanced Recovery After Surgery pathway for gastric cancer surgery
Purpose Time to initiation and completion of adjuvant therapy are critical to improve postoperative oncologic outcomes. This study aims to determine whether an Enhanced Recovery After Surgery (ERAS) pathway for gastric cancer surgery promotes early Return to Intended Oncologic Therapy (RIOT). Methods This is a before-after intervention study including patients with gastric adenocarcinoma who underwent surgery from January 2016 to January 2021. Two periods were denoted based upon the implementation date of our institutional ERAS pathway (June 2018). Our primary outcome was time to RIOT after surgery. Hodges-Lehmann analysis was used to estimate median differences of non-parametric outcomes. Results Seventy patients with gastric adenocarcinoma were included (35 in pre-ERAS period and 35 in post-ERAS period). Fourteen of the pre-ERAS and twenty-two patients of the post-ERAS period received adjuvant therapy. Time to RIOT was reduced in the post-ERAS period (median 39 days, IQR 31–49) by 12 days (95% CI 3–14 days, p = 0.01) compared to the pre-ERAS period (median 51 days, IQR 42–62). Length of hospital stay (LOS) was lower in the ERAS group (6 days, IQR 5–11 vs 10 days, IQR 8–13, p < 0.01). Conclusion Our institutional ERAS pathway for gastric cancer surgery was associated with earlier RIOT and shorter LOS.
- 11 April 2022
- Published by Springer Nature in Current Oncology Reports
- Vol. 24 (9) , 1177-1187
Enhanced Recovery After Surgery (ERAS) in Surgical Oncology
Purpose of the Review The objective of this review is to address the rationale behind the application of the Enhanced Recovery After Surgery (ERAS) protocols that could improve oncologic outcomes in adult patients undergoing major surgery. Recent Findings The implementation of ERAS protocols has been associated with fewer postoperative complications as well as decreased return to intended oncologic treatment (RIOT). However, few studies have analyzed the influence of the application of ERAS protocols and long-term oncologic outcomes, although some of its individual elements have been associated with improvements in oncologic outcomes, including overall survival and disease-free survival. Summary Targeted long-term follow-up studies in specific oncologic procedures are required to determine whether ERAS application results in improved oncologic outcomes.
- 11 April 2022
- Published by Springer Nature in Current Oncology Reports
- Vol. 24 (9) , 1177-1187
Enhanced Recovery After Surgery (ERAS) in Surgical Oncology
Purpose of the Review The objective of this review is to address the rationale behind the application of the Enhanced Recovery After Surgery (ERAS) protocols that could improve oncologic outcomes in adult patients undergoing major surgery. Recent Findings The implementation of ERAS protocols has been associated with fewer postoperative complications as well as decreased return to intended oncologic treatment (RIOT). However, few studies have analyzed the influence of the application of ERAS protocols and long-term oncologic outcomes, although some of its individual elements have been associated with improvements in oncologic outcomes, including overall survival and disease-free survival. Summary Targeted long-term follow-up studies in specific oncologic procedures are required to determine whether ERAS application results in improved oncologic outcomes.